Dupilumab may reduce pruritus and lesion appearance among patients with prurigo nodularis

Prurigo nodularis (PN) is a distressing inflammatory skin condition marked by itchy, reddish lesions.

Dupilumab may reduce pruritus and lesion appearance among patients with prurigo nodularis, according to a comprehensive review of the extensive systemic therapies. The outcomes of the study were published in Journal of Cutaneous Medicine and Surgery.

The primary goal of interventions is to disrupt the destructive itch-scratch cycle associated with Prurigo nodularis, necessitating a multifaceted approach targeting both immune and neural factors. In a recent evidence review, researchers conducted a meticulous search across databases complemented by an exploration of Google Scholar. This resulted in including 88 studies after the elimination of duplicates and irrelevant findings.

Among the different treatments that were scrutinized in this research that identified several promising drugs to solve the inflammatory condition. Dupilumab emerged as a standout by showcasing the efficacy in reducing both pruritus and lesion appearance with notably fewer side effects. Thalidomide and pregabalin also demonstrated effectiveness with concerns over long-term use were also raised due to pain associated with muscle and nerve.